20 20

Transactions on
Data Privacy
Foundations and Technologies

http://www.tdp.cat


Articles in Press

Accepted articles here

Latest Issues

Year 2025

Volume 18 Issue 2
Volume 18 Issue 1

Year 2024

Volume 17 Issue 3
Volume 17 Issue 2
Volume 17 Issue 1

Year 2023

Volume 16 Issue 3
Volume 16 Issue 2
Volume 16 Issue 1

Year 2022

Volume 15 Issue 3
Volume 15 Issue 2
Volume 15 Issue 1

Year 2021

Volume 14 Issue 3
Volume 14 Issue 2
Volume 14 Issue 1

Year 2020

Volume 13 Issue 3
Volume 13 Issue 2
Volume 13 Issue 1

Year 2019

Volume 12 Issue 3
Volume 12 Issue 2
Volume 12 Issue 1

Year 2018

Volume 11 Issue 3
Volume 11 Issue 2
Volume 11 Issue 1

Year 2017

Volume 10 Issue 3
Volume 10 Issue 2
Volume 10 Issue 1

Year 2016

Volume 9 Issue 3
Volume 9 Issue 2
Volume 9 Issue 1

Year 2015

Volume 8 Issue 3
Volume 8 Issue 2
Volume 8 Issue 1

Year 2014

Volume 7 Issue 3
Volume 7 Issue 2
Volume 7 Issue 1

Year 2013

Volume 6 Issue 3
Volume 6 Issue 2
Volume 6 Issue 1

Year 2012

Volume 5 Issue 3
Volume 5 Issue 2
Volume 5 Issue 1

Year 2011

Volume 4 Issue 3
Volume 4 Issue 2
Volume 4 Issue 1

Year 2010

Volume 3 Issue 3
Volume 3 Issue 2
Volume 3 Issue 1

Year 2009

Volume 2 Issue 3
Volume 2 Issue 2
Volume 2 Issue 1

Year 2008

Volume 1 Issue 3
Volume 1 Issue 2
Volume 1 Issue 1


Volume 15 Issue 2


Collaborative Drug Discovery: Inference-level Data Protection Perspective

Balazs Pejo(a),(*), Mina Remeli(b), Adam Arany(c), Mathieu Galtier(d), Gergely Acs(a)

Transactions on Data Privacy 15:2 (2022) 87 - 107

Abstract, PDF

(a) CrySyS Lab, BME, Hungary.

(b) University of Cambridge, United Kingdom. (Work was done while at CrySyS Lab).

(c) Stadius,KUL, Belgium.

(d) Owkin, France

e-mail:pejo @crysys.hu; mincsek @gmail.com; adam.arany @kuleuven.be; mathieu.galtier @owkin.com; acs @crysys.hu


Abstract

Pharmaceutical industry can better leverage its data assets to virtualize drug discovery through a collaborative machine learning platform. On the other hand, there are non-negligible risks stemming from the unintended leakage of participants' training data, hence, it is essential for such a platform to be secure and privacy-preserving. This paper describes a privacy risk assessment for collaborative modeling in the preclinical phase of drug discovery to accelerate the selection of promising drug candidates. After a short taxonomy of state-of-the-art inference attacks we adopt and customize several to the underlying scenario. Finally we describe and experiments with a handful of relevant privacy protection techniques to mitigate such attacks.

* Corresponding author.


ISSN: 1888-5063; ISSN (Digital): 2013-1631; D.L.:B-11873-2008; Web Site: http://www.tdp.cat/
Contact: Transactions on Data Privacy; Vicenç Torra; Umeå University; 90187 Umeå (Sweden); e-mail:tdp@tdp.cat
Note: TDP's web site does not use cookies. TDP does not keep information neither on IP addresses nor browsers. For the privacy policy access here.

 


Vicenç Torra, Last modified: 23 : 16 August 31 2022.